Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDT AustraliaASX:IDT Debt-to-Equity is 0.49 as of Dec. 2025, which is 1533% above its 10-year median of 0.03. The stock has 6 warning signs investors should review. Among 813 Drug Manufacturers companies, IDT Australia ranks worse than 68.76% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for IDT Australia's Debt-to-Equity or its related term are showing as below:
ASX:IDT'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.03 Max: 0.49
Current: 0.49
During the past 13 years, the highest Debt-to-Equity Ratio of IDT Australia was 0.49. The lowest was 0.01. And the median was 0.03.
ASX:IDT's Debt-to-Equity is ranked worse than 68.76% of 813
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs ASX:IDT: 0.49
IDT Australia (ASX:IDT) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
IDT Australia Debt-to-Equity Related Terms
IDT Australia Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for IDT Australia's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, IDT Australia's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDT Australia Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, IDT Australia's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where IDT Australia's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDT Australia (ASX:IDT) has a Debt-to-Equity of 0.49 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on IDT Australia and its competitors. This is 1533% above median its historical median of 0.03. Over the past decade, IDT Australia's Debt-to-Equity has ranged from 0.01 to 0.49. According to the industry distribution chart, IDT Australia ranks #559 out of 813 companies in the Drug Manufacturers industry, placing it in the top 68.8%.
Is IDT Australia's Debt-to-Equity too high?
IDT Australia's current Debt-to-Equity of 0.49 is 1533% above median its 10-year median of 0.03. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.49. The Drug Manufacturers industry median Debt-to-Equity is 0.27. IDT Australia's value of 0.49 is 81.5% above this industry median. Based on the distribution chart, IDT Australia ranks #559 out of 813 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does IDT Australia's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, IDT Australia ranks #559 out of 813 companies for Debt-to-Equity. This places IDT Australia in the lower half of its industry. The industry median Debt-to-Equity is 0.27. IDT Australia's value of 0.49 is 81.5% above this benchmark. Historically, IDT Australia's own Debt-to-Equity has ranged from 0.01 to 0.49 over the past decade. While the company's 10-year median is 0.03 vs. the industry median of 0.27, IDT Australia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDT Australia's current Debt-to-Equity of 0.49 is 81.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on IDT Australia and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDT Australia's current Debt-to-Equity is 0.49, which is 1533% above median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDT Australia stock overvalued right now?
Based on GuruFocus' analysis, IDT Australia (ASX:IDT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.17, compared to a current price of A$0.03 — trading 80% below its estimated fair value. The current Debt-to-Equity is 0.49, which is 1533% above median its 10-year median of 0.03 and 81.5% above the Drug Manufacturers industry median of 0.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For IDT Australia (ASX:IDT), the current Debt-to-Equity is 0.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
IDT Australia Ltd produces, develops, and supplies pharmaceutical products. It is engaged in the provision of research and development and other technical services for the pharmaceutical and allied industries. The company is involved in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging, and pharmacy services. The company operates in Australia, Asia, Europe, and the USA.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IDT has been successfully added to your 
